Trial
NCT00648739
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
B-cell Chronic Lymphocytic Leukemia
Intervention
Samalizumab
Why stopped
The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-05